Neomatrix mission is to generate the fastest next generation cancer vaccines to selectively eliminate tumor cells in the body.

Our proprietary platform is unique and combines a deep knowledge of cancer biology and Immuno-Oncology, cutting-edge technologies to identify patient’s tumor neoantigens, innovative design and production of fully-synthetic, personalized DNA vaccines, a potent delivery system to maximize the immune response and the synergic effect with immune checkpoint inhibitors.

Latest News

21 November, 2024
Neomatrix Secures EUR 1.5 Million in Funding to Advance Personalized Cancer Vaccine Development

Neomatrix, a pioneering biotech firm, has successfully closed EUR 1.5 million in additional funding led by existing investors 2Invest AG and i2i Capital Limited. This new investment will be crucial in completing the regulatory development for its proprietary personalized cancer vaccines and exploring innovative combination strategies (read more)

8-10 November, 2024
Neomatrix presenting a Poster at SITC’s 39th Annual Meeting

Neomatrix presenting a Poster at SITC’s 39th Annual Meeting, the leading member-driven organization focused on cancer immunotherapy. At SITC’s Annual Meeting, international leaders from academia, regulatory and government agencies, as well as industry (read more)